IQVIA Holdings Inc (IQV) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific.
Total Revenue Chart for IQVIA Holdings Inc
IQVIA Holdings Inc (IQV) revenue for FY2025 was USD 16.3B, a 5.9% change from FY2024. IQVIA Holdings Inc's revenue grew from USD 3.9B in 2010 to USD 16.3B in 2025 (315.6% over 15 years). Earnings per share grew from USD 1.90 in 2011 to USD 7.84 in 2025 (313.5%). Revenue compound annual growth rate: 5-year CAGR of 7.5%, 10-year CAGR of 11.0%.
Total Revenue (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $44.89B
- Implied Share Price
- $272.39
- Enterprise Value
- $59.22B
- Revenue (TTM)
- $17.31B
- EBITDA
- $3.12B
- Profit Margin
- 8.05%
- Trailing P/E
- 33.14
- Forward P/E
- 18.98
- Price/Book (MRQ)
- 6.81
- Price/Sales (TTM)
- 2.59
- EV/EBITDA
- 16.66
- EV/Revenue
- 3.42
- Dividend Yield
- —
- Book Value
- $40.41
- Free Cash Flow (FY2025)
- $2.05B
- Free Cash Flow Yield
- 4.57%
Snapshot as of 30th October 2026 — not point-in-time controlled, may lag the live market by a few days.